Nexalin Technology (NXL) Operating Leases (2021 - 2023)

Nexalin Technology (NXL) posted quarterly Operating Leases of $43026.0 for Q1 2023, up 864.06% quarter-over-quarter from $4463.0 in Q4 2022.

Nexalin Technology (NXL) Operating Leases (2021 - 2023) Analysis & Trends

Nexalin Technology's Operating Leases history runs 3 years deep, the most recent figure standing at $43026.0 for Q1 2023.

In Q1 2023, Operating Leases changed N/A year-over-year to $43026.0; the TTM figure through Mar 2023 stood at $43026.0 (changed N/A YoY), while the FY2022 annual figure was $4463.0, down 95.04% from the prior year.
Operating Leases for Q1 2023 stood at $43026.0, up from $4463.0 in the prior quarter.
The five-year high for Operating Leases was $89934.0 in Q4 2021, with the low at $4463.0 in Q4 2022.
The 3-year median for Operating Leases is $30330.0 (2022), against an average of $38764.2.
Peak annual rise in Operating Leases reached 95.04% in 2022, while the deepest fall reached 95.04% in 2022.
Nexalin Technology's Operating Leases stood at $89934.0 in 2021, then plunged by 95.04% to $4463.0 in 2022, then soared by 864.06% to $43026.0 in 2023.
Business Quant data shows NXL's Operating Leases at $43026.0 in Q1 2023, $4463.0 in Q4 2022, and $17634.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn
10	Nexalin Technology	7.00 Mn	6.00 Mn	8,897.00

Download Data